

**UNITED STATES OF AMERICA**  
**Before the**  
**SECURITIES AND EXCHANGE COMMISSION**

**SECURITIES EXCHANGE ACT OF 1934**

**Release No. 88142 / February 7, 2020**

The Securities and Exchange Commission (“Commission”) announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of trading in the securities of Aethlon Medical, Inc. (“AEMD”) of San Diego, California at 9:30 a.m. EST on February 7, 2020, and terminating at 11:59 p.m. EST on February 21, 2020.

The Commission temporarily suspended trading in the securities of AEMD because of (i) concerns regarding the accuracy and adequacy of information in the marketplace since at least January 22, 2020, that appears to be disseminated by third party promoters that are, purportedly, not affiliated with AEMD about, among other things, the viability of the company’s product to treat the coronavirus, and (ii) questions regarding recent and unusual market activity since at least January 22, 2020. AEMD is a Nevada corporation based in San Diego, California. Its stock is listed on NASDAQ under the symbol AEMD. The order was entered pursuant to Section 12(k) of the Exchange Act.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

If any broker-dealer or other person has any information which may relate to this matter, contact Steven G. Rawlings, Assistant Regional Director, New York Regional Office, at (212) 336-0149. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.